Progenity Stock

Progenity Share Buybacks

Delisted

The Share Buybacks of Progenity (PROG) as of Aug 16, 2026 is 172.22 M USD. In the previous year, Share Buybacks was 137.74 M USD — a change of 25.03% (higher).

Share Buybacks

172.22 MUSD

YoY

25.03%

Last updated:

Share Buybacks of Progenity is 2026 172.22 M USD. Share Buybacks of Progenity was 2025 137.74 M USD. It decreases by 25.03% higher compared to the previous year.
Access this data via the Eulerpool API

Progenity Stock analysis

What does Progenity do? Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Progenity stock

Share Buybacks of Progenity is 172.22 M USD in 2026.

Share Buybacks of Progenity changed from 137.74 M USD to 172.22 M USD, representing a 25.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Progenity since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Progenity historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Progenity

All Key Metrics — Progenity